Inflammatory immune cells predict survival, relapse in MM, WashU-led study finds

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard of care, despite limited evidence to guide the optimal duration of treatment.

July 17, 2026

Vol.52 No.28

Drugs & Targets

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

FDA approved Sarclisa Escena (isatuximab-irfc) for subcutaneous injection for multiple myeloma indications.

July 17, 2026

Vol.52 No.28

Clinical Roundup

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

The Multiple Myeloma Research Foundation announced that the first patient has been enrolled in the groundbreaking Horizon Two clinical trial that aims to identify the best treatments and treatment combinations for patients with high-risk, newly diagnosed multiple myeloma.

July 02, 2026

Vol.52 No.26

Clinical Roundup

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

June 05, 2026

Vol.52 No.22

Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies.

April 03, 2026

Vol.52 No.13

By Nicholas Richardson

Clinical Roundup

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Oral mezigdomide in combination with carfilzomib and dexamethasone demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to positive interim phase III results from the SUCCESSOR-2 study.

March 13, 2026

Vol.52 No.10

Inflammatory immune cells predict survival, relapse in MM, WashU-led study finds

YOU MAY BE INTERESTED IN

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

Teclistamab improves outcomes in relapsed MM, phase III trial finds

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Renew today!

Subscriber content

Never miss an issue!

Login

Inflammatory immune cells predict survival, relapse in MM, WashU-led study finds

YOU MAY BE INTERESTED IN

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

Teclistamab improves outcomes in relapsed MM, phase III trial finds

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Never miss an issue!

Login

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers